SBIR-STTR Award

An Interactive Graphical Application for Next-Generation Surveillance of Hospital-Acquired Infections using Whole Genome Sequencing and Advanced Analytics
Award last edited on: 2/27/2019

Sponsored Program
SBIR
Awarding Agency
NSF
Total Award Amount
$1,376,997
Award Phase
2
Solicitation Topic Code
BT
Principal Investigator
Susanna L Lamers

Company Information

BioInfoExperts LLC

Po Box 693718 Bayou Lane
Thibodaux, LA 70301
   (985) 413-0455
   info@bioinfox.com
   www.bioinfox.com
Location: Single
Congr. District: 06
County: Lafourche Parish

Phase I

Contract Number: 1648053
Start Date: 12/1/2016    Completed: 11/30/2017
Phase I year
2016
Phase I Amount
$225,000
The broader impact/commercial potential of this Small Business Innovative Research (SBIR) project is to addresses challenges in understanding, analyzing, and visualizing data from large sets of unsorted, noisy data associated with massive next generation sequencing (NGS). These projects frequently are focused on pathogen transmission patterns, drug resistance, and general epidemiology and employ a process called "clustering"; however, current clustering tools are rudimentary, not intuitive, poorly documented and provide little help with data management and visualization. The goal is to develop software for Clustering and Associating Sequences in a Personalized Environment (CASPER). This software will bring much needed state-of-the-art software engineering and visualization technology to NGS sequence analysis that results in finding correlations in disparate data-types that are currently overlooked. Further, this software addresses commercial demands for integrated bioinformatics that speed discovery using contemporary and innovative technologies that enhance the end-user experience. This will increase the ability of researchers to combat major health challenges, perform biological research and develop effective interventions to prevent and treat illness.This SBIR Phase I project proposes to develop a bioinformatics application designed for biological researchers to explore the evolutionary relationships in very large sequence data sets. These data are commonly associated with multiple annotations and there are time-consuming hurdles in acquiring a meaningful visual representation of their relationships, especially in combination with geospatial, demographic and/or temporal data. Further, while many bioinformatics applications/approaches focus on achieving a single analytical task, the proposed software focuses extensively on the end-user, so that efficient and accurate data processing are combined with rich and meaningful graphical outputs. In addition, it will provide a graphical database management system (GDBS) built around the researcher's data as it is imported, resulting in fewer errors. A database linked to analytical results allows for rapid result filtering as well as instantaneous updates as data sets expand over time. Integrated visualization tools allow researchers to produce varied network graphics that can show how results change over time. In Phase I, the goal is to focus on developing a framework to optimize the end-user experience (e.g., speed, intuitive design, useful formatting of results). The project brings together a powerful and unique group of scientists in the fields of software design, computer modeling, data visualization, bioinformatics, genetic analysis and epidemiology.

Phase II

Contract Number: 1830867
Start Date: 9/15/2018    Completed: 8/31/2020
Phase II year
2018
(last award dollars: 2022)
Phase II Amount
$1,151,997

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase II project will be a user-friendly and scalable infection control surveillance software platform using advanced biotech and data analytics for monitoring hospital-acquired infection. There is a significant clinical problem in hospitals, where 1 in 25 people who check in will develop a hospital acquired infection. Currently, hospital infection control practitioners (ICPs) have few analytical tools to identify the source of these infections, which can be deadly and cost the health care industry an estimate of $45 billion year. The innovation under development harnesses advanced epidemiological approaches in an easy-to-use application that will enable ICPs to use bacterial genetics as a means to monitor infectious spread within their system so that their sources can be eliminated.The intellectual merit of this SBIR Phase II proposal is to develop an infection control surveillance software system using whole-genome sequencing of pathogens and advanced data analytics. The innovation addresses the critical lack of accessible genetic analysis applications designed for local infection control surveillance. Hospitals are observing ever increasing rates of antibiotic resistant infections. These are expensive, endanger patients, and are becoming harder to trace as medical care becomes more complex and spread over multiple facilities. Unfortunately, ICPs have few new tools, other than best hygiene practices, to reduce their mounting infection rates. Decades of research has revealed that epidemiological surveillance using genetic analysis provides a robust level of pathogen traceability; however, this knowledge has not been transferred into hospitals where it is critically needed, due to a lack of technical infrastructure and analytical accessibility. In this Phase II project, the goal is to complete the development of a software application that will enable ICPs to easily and accurately process bacterial genetic data in their own offices and generate rich, meaningful and easy to interpret reports concerning bacterial spread in their networks. ICPs will be warned when infection sources relate to each other, suggesting that a deeper investigation is needed. The result is that infection sources, which are currently missed, will be proactively identified and targeted.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.